Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-20-186895
Filing Date
2020-07-02
Accepted
2020-07-02 16:37:08
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B5 d947820d424b5.htm 424B5 313750
2 GRAPHIC g947820g33e42.jpg GRAPHIC 45835
  Complete submission text file 0001193125-20-186895.txt   378032
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-227209 | Film No.: 201010001
SIC: 2834 Pharmaceutical Preparations